Do you want to read an article? Please log in or register.
Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
COPD
COMMENTED
Related content
COPDEmphysema
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)
Respir Med
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM
doi: 10.1016/j.rmed.2024.107846
RECOMMENDED
COPD
Prognostic risk prediction model for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD): a systematic review and meta-analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res
Xu Z, Li F, Xin Y, Wang Y, Wang Y
doi: 10.1186/s12931-024-03033-4
COMMENTED
COPD
Exacerbation history and risk of myocardial infarction and pulmonary embolism in chronic obstructive pulmonary disease
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Wallström O, Stridsman C, Lindberg A, Nyberg F, Vanfleteren LEGW
doi: 10.1016/j.chest.2024.07.150
RECOMMENDED
COPD
Use of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitor is Associated with reduced Emergency Room Visits and Hospitalization in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Diabetes Mellitus
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Shanmugavel Geetha H, Teo YX, Ravichandran S, Perkitt NR, Gogtay M, Lal A, Abraham GM, Trivedi N
doi: 10.1016/j.rmed.2024.107819
RECOMMENDED
COPD
Treatment intensity level as a proxy for severity of chronic obstructive pulmonary disease: A risk stratification tool
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Respir Med
Lauridsen MD, Grøntved S, Fosbøl E, Johnsen SP, Quint JK, Weinreich UM, Valentin JB
doi: 10.1016/j.rmed.2024.107742
RECOMMENDED
COPD
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med
Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS, COURSE study investigators
doi: 10.1016/S2213-2600(24)00324-2
RECOMMENDED
COPDInterstitial Lung Disease
Pulmonary Rehabilitation and Functional Independence: Impact on Survival in Patients with Fibrotic Interstitial Lung Disease or Chronic Obstructive Pulmonary Disease
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Elmiger A, Marcin T, Bovet L, Brun P, Guler SA
doi: 10.1016/j.rmed.2024.107933
Further Publications
Benefit of dual bronchodilator therapy on exacerbations in former and current smokers with chronic obstructive pulmonary disease in real-world clinical practice: a multicenter validation study (TOReTO)
Respir Res
Lai YT, Tsai YH, Hsieh MJ, Chen NH, Cheng SL, Tao CW, Wei YF, Wu YK, Chan MC, Liu SF, Hsu WH, Yang TM, Liu CL, Kuo PH, Lin MS
doi: 10.1186/s12931-024-02971-3
COPDLung Cancer
Construction and Validation of a Nomogram Prediction Model for Death Risk in Patients with Chronic Obstructive Pulmonary Disease Complicated by Hypercapnic Respiratory Failure in the Intensive Care Unit
Respir Med
Zhang Y, Chen H, Hu S, Chen C, Chen W
doi: 10.1016/j.rmed.2025.108188